OptiNose, Inc.

at no cost to new commercial patients. Again, that was put in place in response to the pandemic. It really helped us achieve record market share in the second and third quarter, and was very well received, and we expect the benefits of getting those patients on board to continue, but it did cost us some average net revenue per prescription in the second quarter. For the fourth quarter, we're not gonna give specific guidance, but I'll comment that if you look historically, we've been above $200 for average net revenue per prescription every third quarter and fourth quarter from launch. And our guidance remains the same, that we continue to expect the yearly average net revenue per prescription to increase throughout the year because of the reasons I mentioned earlier. With respect to revenue, You know, we had, if you recall, we had revenue guidance out pre-COVID. We did withdraw that guidance, as many companies did, in response to the pandemic when we had our 2Q call, I believe, in May. And, you know, at this point, we're not comfortable putting new guidance out there for the full year. I will point, though, to the prescription growth. that we've continued to see in spite of the pandemic. I think 11%, Q2 to Q3 in TRX growth, and the continued strength of the average net revenue per script, which I just talked about. So we'd keep both of those in mind as you're thinking about what 4Q will look like.

Thank you so much.

Next question, David Steinberg with Jefferies.